Arcutis Biotherapeutics, Inc., a leading commercial-stage medical dermatology company, has announced the appointment of David Topper as its Chief Financial Officer (CFO) effective April 10, 2024. Topper's appointment marks a significant development for Arcutis as the company continues its mission of advancing meaningful innovations in immuno-dermatology.
Topper brings a wealth of experience to his new role, having served as CFO at Inmagene Biopharmaceuticals, a global clinical-stage pharmaceutical company. His proven track record in leading and advising on capital markets activities, including initial public offerings, mergers and acquisitions, and debt financings, positions him well to drive Arcutis' financial strategy forward.
Frank Watanabe, President and CEO of Arcutis, expressed his enthusiasm for Topper's appointment, stating, "We could not be more pleased to welcome David as chief financial officer at this transformational time. His extensive experience in finance, M&A, and capital markets will be a tremendous asset as we continue to advance the commercial operations of Arcutis and build the leading innovation-driven medical dermatology company."
Topper's appointment comes as Arcutis prepares for potential future endeavors, including a potential public listing. His expertise in capital markets and finance will play a crucial role in supporting Arcutis' growth and expansion initiatives.
In his previous roles, Topper has demonstrated a deep understanding of the pharmaceutical industry and a keen ability to navigate complex financial landscapes. Prior to his tenure at Inmagene, he held significant positions at General Atlantic, Frazier Life Sciences, and J.P. Morgan, where he served as co-head of Equity Capital Markets and vice chairman.
Topper's academic background includes an MBA from Stanford University and a B.A. from Duke University, further solidifying his credentials as a seasoned financial executive.
Arcutis Biotherapeutics, Inc. is known for its commitment to addressing the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a growing portfolio of FDA-approved products and a robust pipeline of clinical programs, Arcutis is at the forefront of dermatology innovation.
